145 related articles for article (PubMed ID: 22377772)
1. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
[TBL] [Abstract][Full Text] [Related]
2. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
4. [Study of use of pemetrexed in non-small cell lung cancer].
Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed and maintenance therapy for non-small cell lung cancer.
Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
[No Abstract] [Full Text] [Related]
6. Pemetrexed-induced hyperpigmentation of the skin.
Schallier D; Decoster L; de Greve J
Anticancer Res; 2011 May; 31(5):1753-5. PubMed ID: 21617235
[TBL] [Abstract][Full Text] [Related]
7. [Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].
Konishi A; Kitada N; Nanjo S; Tanaka S; Tomii K; Katakami N; Hashida T
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1507-10. PubMed ID: 23064061
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.
Katsenos S; Psara A; Panagou C
J Oncol Pharm Pract; 2013 Mar; 19(1):93-4. PubMed ID: 22357637
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
Bearz A; Garassino I; Cavina R; Favaretto A; Boccalon M; Talamini R; Berretta M; Spazzapan S; Simonelli C; Santoro A; Tirelli U
Lung Cancer; 2008 May; 60(2):240-5. PubMed ID: 18022729
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed-induced lung toxicity: a case report.
Breuer S; Nechushtan H
Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):76-7. PubMed ID: 21924594
[No Abstract] [Full Text] [Related]
11. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.
Gridelli C; Di Maio M
Expert Opin Pharmacother; 2010 Feb; 11(2):321-4. PubMed ID: 20053140
[TBL] [Abstract][Full Text] [Related]
12. [Safety and effectiveness of pemetrexed in patients with non-small cell lung cancer in Japan - analysis of post-marketing surveillance].
Okubo S; Kobayashi N; Taketsuna M; Kaneko N; Enatsu S; Nishiuma S
Gan To Kagaku Ryoho; 2014 Apr; 41(4):475-81. PubMed ID: 24743364
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed-induced edema of the eyelid.
Kurata T; Tamura K; Okamoto I; Satoh T; Nakagawa K; Fukuoka M
Lung Cancer; 2006 Nov; 54(2):241-2. PubMed ID: 16996165
[TBL] [Abstract][Full Text] [Related]
14. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
[TBL] [Abstract][Full Text] [Related]
15. [Management and maintenance of pemetrexed monotherapy regimen - initial experience of pretreated non-small cell lung cancer].
Takase M; Maruoka H; Ametani F; Takahashi M; Shibata K
Gan To Kagaku Ryoho; 2012 Apr; 39(4):563-5. PubMed ID: 22504678
[TBL] [Abstract][Full Text] [Related]
16. Radiation recall dermatitis with pemetrexed.
Hureaux J; Le Guen Y; Tuchais C; Savary L; Urban T
Lung Cancer; 2005 Nov; 50(2):255-8. PubMed ID: 16111784
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.
Brade A; Bezjak A; MacRae R; Laurie S; Sun A; Cho J; Leighl N; Pearson S; Southwood B; Wang L; McGill S; Iscoe N; Shepherd FA
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1395-401. PubMed ID: 20605367
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
19. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.
Bearz A; Garassino I; Tiseo M; Caffo O; Soto-Parra H; Boccalon M; Talamini R; Santoro A; Bartolotti M; Murgia V; Berretta M; Tirelli U
Lung Cancer; 2010 May; 68(2):264-8. PubMed ID: 19632738
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E; Casillas M; Cassinello A
Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]